19,211 Shares in Haleon plc (NYSE:HLN) Acquired by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB acquired a new stake in shares of Haleon plc (NYSE:HLN) in the third quarter, HoldingsChannel.com reports. The fund acquired 19,211 shares of the company’s stock, valued at approximately $203,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Fortitude Family Office LLC bought a new position in shares of Haleon during the third quarter worth $28,000. Toronto Dominion Bank boosted its holdings in shares of Haleon by 3,470.0% during the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock valued at $38,000 after purchasing an additional 3,470 shares during the last quarter. Prospera Private Wealth LLC bought a new position in shares of Haleon during the 3rd quarter valued at about $57,000. BOKF NA grew its position in shares of Haleon by 68.8% during the second quarter. BOKF NA now owns 6,972 shares of the company’s stock valued at $58,000 after purchasing an additional 2,842 shares in the last quarter. Finally, Rothschild Investment LLC purchased a new stake in shares of Haleon in the second quarter worth about $60,000. Institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

NYSE HLN opened at $9.71 on Thursday. The business’s 50 day moving average price is $9.74 and its 200-day moving average price is $9.55. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80. The company has a market cap of $43.95 billion, a P/E ratio of 28.56, a P/E/G ratio of 2.95 and a beta of 0.28. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Analysts Set New Price Targets

Several research firms have weighed in on HLN. UBS Group upgraded Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Morgan Stanley raised their target price on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a report on Friday, September 20th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Haleon has a consensus rating of “Buy” and a consensus target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.